163 related articles for article (PubMed ID: 37644680)
1. Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population.
Baek HS; Ha J; Kim K; Bae J; Kim JS; Kim S; Lim DJ; Kim C
J Korean Med Sci; 2023 Aug; 38(34):e264. PubMed ID: 37644680
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population.
Baek HS; Ha J; Kim K; Bae JS; Kim JS; Kim S; Lim DJ; Kim CM
Endocrinol Metab (Seoul); 2024 Apr; 39(2):310-323. PubMed ID: 38590123
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of active surveillance versus early surgery for thyroid micropapillary carcinoma based on diagnostic and treatment norms in China.
Lai M; Zhang MM; Qin QQ; An Y; Li YT; Yuan WZ
Front Endocrinol (Lausanne); 2023; 14():1166433. PubMed ID: 37664842
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma.
Lang BH; Wong CK
Eur J Endocrinol; 2015 Sep; 173(3):367-75. PubMed ID: 26104754
[TBL] [Abstract][Full Text] [Related]
5. Thyroid lobectomy as a cost-effective approach in low-risk papillary thyroid cancer versus active surveillance.
Youssef MR; Attia AS; Omar M; Aboueisha M; Freeman MN; Shama M; Kandil E
Surgery; 2022 Jan; 171(1):190-196. PubMed ID: 34384606
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer.
Venkatesh S; Pasternak JD; Beninato T; Drake FT; Kluijfhout WP; Liu C; Gosnell JE; Shen WT; Clark OH; Duh QY; Suh I
Surgery; 2017 Jan; 161(1):116-126. PubMed ID: 27839930
[TBL] [Abstract][Full Text] [Related]
7. Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study.
Kim K; Choi JY; Kim SJ; Lee EK; Lee YK; Ryu JS; Lee KE; Moon JH; Park YJ; Cho SW; Park SK
Thyroid; 2022 Jun; 32(6):648-656. PubMed ID: 35570657
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review.
Baek HS; Jeong CH; Ha J; Bae JS; Kim JS; Lim DJ; Kim CM
Cancer Manag Res; 2021; 13():6721-6730. PubMed ID: 34471385
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
14. Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance.
Lin JF; Jonker PKC; Cunich M; Sidhu SB; Delbridge LW; Glover AR; Learoyd DL; Aniss A; Kruijff S; Sywak MS
Surgery; 2020 Jan; 167(1):110-116. PubMed ID: 31543327
[TBL] [Abstract][Full Text] [Related]
15. Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults.
Horiguchi K; Yoshida Y; Iwaku K; Emoto N; Kasahara T; Sato J; Shimura H; Shindo H; Suzuki S; Nagano H; Furuya F; Makita N; Matsumoto F; Manaka K; Mitsutake N; Miyakawa M; Yokoya S; Sugitani I
Endocr J; 2021 Jul; 68(7):763-780. PubMed ID: 33762511
[TBL] [Abstract][Full Text] [Related]
16. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
Wali AR; Park CC; Brown JM; Mandeville R
Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
[TBL] [Abstract][Full Text] [Related]
17. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
[TBL] [Abstract][Full Text] [Related]
18. Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma.
Sugitani I; Ito Y; Takeuchi D; Nakayama H; Masaki C; Shindo H; Teshima M; Horiguchi K; Yoshida Y; Kanai T; Hirokawa M; Hames KY; Tabei I; Miyauchi A
Thyroid; 2021 Feb; 31(2):183-192. PubMed ID: 33023426
[No Abstract] [Full Text] [Related]
19. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
